Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Executive Summary
Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.
You may also be interested in...
Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.
Myeloma Milestones: Selinexor May Be Next Novel Agent While Established Drugs Expand Indications
Karyopharm's selinexor could be the next novel drug approved for multiple myeloma, which has seen a deluge of new treatment regimens. With room for improvement, the pipeline is full of milestones for approved and new therapies.
Multiple Myeloma: Pricing And Reimbursement Challenges Escalate Even As Blockbusters Go Generic
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.
Need a specific report? 1000+ reports available
Buy Reports